Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
?? Here's a copy of a post and reply from another board.. ?? Good points IMO
Anonymous36
Wasn't the next news release going to be the enrollment of the first patient? How come that is taking so long?
Replies (1)
Jack6
They are dropping the ball in regards to starting phase 3. They were approved to go into phase 3 like 2 months ago and they are still choosing clinical sites. They couldn't have moved any slower. This will bite them in the rear end. Phase 3 should have started a month ago.
"as swiftly as possible" Looking good!!!
$RLFTF (opinion article) Relief Therapeutics (OTC: RLFTF) to get FDA approval by JAY LORRENCE OCTOBER 5, 2020 BIOTECH STOCKS, FEATURED stock
https://moneymidnight.com/2020/10/relief-therapeutics-otc-rlftf-to-get-fda-approval/?utm_source=rss&utm_medium=rss&utm_campaign=relief-therapeutics-otc-rlftf-to-get-fda-approval
$RLFTF Possible treatment for COVID-19 related respiratory failure – FULL – Jonathan Javitt Oct 4, 2020
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.
U2, thanks
..sorry.. I thought you were being a wise...^^%$ w/me earlier..
Javitt is in Control..
NYC to Shut Businesses, Schools in Parts of Brooklyn, Queens http://a.msn.com/00/en-us/BB19H4z6?ocid=st
NYC to Shut Businesses, Schools in Parts of Brooklyn, Queens http://a.msn.com/00/en-us/BB19H4z6?ocid=st
Coming through Israel helps w/many roadblocks.. and you Know Jared will now be aware of RLF-100 for sure ..
$RLFTF NeuroRX on the cusp of releasing a life-saving COVID-19 treatment https://www.jpost.com/health-science/neurorx-on-the-cusp-of-releasing-a-life-saving-covid-19-treatment-644470
$RLFTF NeuroRX on the cusp of releasing a life-saving COVID-19 treatment https://www.jpost.com/health-science/neurorx-on-the-cusp-of-releasing-a-life-saving-covid-19-treatment-644470
$RLFTF RLF-100 Will be so much more than a Covid-19 treatment in the long run.
CBD Will Soon Be a $5.3 Billion Business, But Does It Work? http://a.msn.com/05/en-us/BB19EtN6?ocid=st
They're saying the Pres. got some regeneron zinc and vit-d for the covid-19 today.. we'll see..?? Dr. Oz is supposed to be on Hannity tonight..??
$RLFTF Stanford University: Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19
Clinical Trial NCT04360096
Website
https://racetoacure.stanford.edu/clinical-trials/486
DD by tiggerifficm4
$RLFTF Good DD by Gemstone (post)
I highly recommend that everyone watch Dr. Javitt’s interview with Dr. Yo for themselves. I carefully listened to the interview, and heard several positive statements. In my opinion, Dr. Javitt’s disposition was the same as in his previous interview with Dr. Yo.
1) Dr. Javitt stated that in order to obtain an FDA EUA, the requirement is that the drug is safe and “MAY” be effective. He further explained that they ALREADY have evidence to meet these requirements for the FDA EUA, and referenced the clinical data available from the 21 patients treated with RLF-100 under the expanded access program. Thus, the data expected at the end of October from the ongoing clinical trial is NOT needed for FDA EUA, but will be used to meet the full FDA drug approval standard of “safe and effective”.
2) Israel has granted compassionate care protocol across the country for RLF-100.
3) The company has a cooperative agreement with NIH, where NIH is testing RLF-100 against the flu and other viruses (that kill people by attacking the lungs). If effective, there will be a broader use for the drug.
4) Doctors in Germany have used VIP in an inhaled form on a limited number of patients, and those patients are all back home.
5) Dr. Javitt reiterated the following information:
One of the most interesting things they’ve seen is that patients who have survived critical COVID-19 after being on ventilators, had twice the amount of VIP in their bloodstream than similar patients who died.
Dr. Javitt stated that VIP is how the lung recovers from all kinds of injuries. On an evolutionary basis, he views VIP as a perfect molecule.
SARS-CoV-2 binds to the ACE2 receptor on alveolar type 2 cells. The alveolar type 2 cells are critical to the function of the lungs. When the virus goes inside the alveolar type 2 cells, it shuts down the production of surfactant in the lungs. The surfactant keeps the lung coated and allows oxygen to pass across the lung. When you no longer produce surfactant, you cannot oxygenate your blood and that is the beginning of COVID-19 complications. If they can preserve the alveolar type 2 cells early in the disease, there is a chance they can make a significant impact on COVID-19.
Dr. Javitt interview
$RLFTF Stanford University: Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19
Clinical Trial NCT04360096
Website
https://racetoacure.stanford.edu/clinical-trials/486
DD by tiggerifficm4
$RLFTF Good DD by Gemstone (post)
I highly recommend that everyone watch Dr. Javitt’s interview with Dr. Yo for themselves. I carefully listened to the interview, and heard several positive statements. In my opinion, Dr. Javitt’s disposition was the same as in his previous interview with Dr. Yo.
1) Dr. Javitt stated that in order to obtain an FDA EUA, the requirement is that the drug is safe and “MAY” be effective. He further explained that they ALREADY have evidence to meet these requirements for the FDA EUA, and referenced the clinical data available from the 21 patients treated with RLF-100 under the expanded access program. Thus, the data expected at the end of October from the ongoing clinical trial is NOT needed for FDA EUA, but will be used to meet the full FDA drug approval standard of “safe and effective”.
2) Israel has granted compassionate care protocol across the country for RLF-100.
3) The company has a cooperative agreement with NIH, where NIH is testing RLF-100 against the flu and other viruses (that kill people by attacking the lungs). If effective, there will be a broader use for the drug.
4) Doctors in Germany have used VIP in an inhaled form on a limited number of patients, and those patients are all back home.
5) Dr. Javitt reiterated the following information:
One of the most interesting things they’ve seen is that patients who have survived critical COVID-19 after being on ventilators, had twice the amount of VIP in their bloodstream than similar patients who died.
Dr. Javitt stated that VIP is how the lung recovers from all kinds of injuries. On an evolutionary basis, he views VIP as a perfect molecule.
SARS-CoV-2 binds to the ACE2 receptor on alveolar type 2 cells. The alveolar type 2 cells are critical to the function of the lungs. When the virus goes inside the alveolar type 2 cells, it shuts down the production of surfactant in the lungs. The surfactant keeps the lung coated and allows oxygen to pass across the lung. When you no longer produce surfactant, you cannot oxygenate your blood and that is the beginning of COVID-19 complications. If they can preserve the alveolar type 2 cells early in the disease, there is a chance they can make a significant impact on COVID-19.
Dr. Javitt interview
SWX: RLF
0.54 CHF +0.0040 (0.75%)
Oct 2, 3:37 PM
$RLFTF 4sure RE: All should tweet him about the inhaler RLF-100
I am almost positive they will get RLF-100 .. you know Jared knows about it.. W/Israel using it Nation wide and we're the one down the line that they turn to and it has an effective change.. maybe the inhaled like you said.. for the whole team.
..just went to twitter to send 'em some blessing and RLF-100 was included in the tweet.. gotta send 'em the best ya know.. ;)
..so as a full service broker will you be insuring us against any lost greenbacks ..?
Moderna CEO says its coronavirus vaccine won't be ready until spring of next year https://www.cbsnews.com/news/covid-vaccine-spring-2021-moderna-ceo/ via @cbsmoneywatch
Moderna CEO says its coronavirus vaccine won't be ready until spring of next year https://www.cbsnews.com/news/covid-vaccine-spring-2021-moderna-ceo/ via @cbsmoneywatch
Luke Hutchison woke up in the middle of the night with chills and a fever after taking the Covid-19 booster shot in Moderna’s vaccine trial. Another coronavirus vaccine trial participant, testing Pfizer’s candidate, similarly woke up with chills, shaking so hard he cracked a tooth after taking the second dose.
https://www.cnbc.com/2020/10/01/coronavirus-vaccine-trial-participants-exhaustion-fever-headaches.html
- bostrom post from the RVVTF board
..just a copy.. original thread at the ya- ho, o board.. ;) "not mine" Thought I'd repost here.. good points
$RLFTF Good DD by Gemstone (post)
I highly recommend that everyone watch Dr. Javitt’s interview with Dr. Yo for themselves. I carefully listened to the interview, and heard several positive statements. In my opinion, Dr. Javitt’s disposition was the same as in his previous interview with Dr. Yo.
1) Dr. Javitt stated that in order to obtain an FDA EUA, the requirement is that the drug is safe and “MAY” be effective. He further explained that they ALREADY have evidence to meet these requirements for the FDA EUA, and referenced the clinical data available from the 21 patients treated with RLF-100 under the expanded access program. Thus, the data expected at the end of October from the ongoing clinical trial is NOT needed for FDA EUA, but will be used to meet the full FDA drug approval standard of “safe and effective”.
2) Israel has granted compassionate care protocol across the country for RLF-100.
3) The company has a cooperative agreement with NIH, where NIH is testing RLF-100 against the flu and other viruses (that kill people by attacking the lungs). If effective, there will be a broader use for the drug.
4) Doctors in Germany have used VIP in an inhaled form on a limited number of patients, and those patients are all back home.
5) Dr. Javitt reiterated the following information:
One of the most interesting things they’ve seen is that patients who have survived critical COVID-19 after being on ventilators, had twice the amount of VIP in their bloodstream than similar patients who died.
Dr. Javitt stated that VIP is how the lung recovers from all kinds of injuries. On an evolutionary basis, he views VIP as a perfect molecule.
SARS-CoV-2 binds to the ACE2 receptor on alveolar type 2 cells. The alveolar type 2 cells are critical to the function of the lungs. When the virus goes inside the alveolar type 2 cells, it shuts down the production of surfactant in the lungs. The surfactant keeps the lung coated and allows oxygen to pass across the lung. When you no longer produce surfactant, you cannot oxygenate your blood and that is the beginning of COVID-19 complications. If they can preserve the alveolar type 2 cells early in the disease, there is a chance they can make a significant impact on COVID-19.
Dr. Javitt interview
Lets GO GL Brands!!!
..just heard opinion from an old CDC director He believes possible vaccine for limited front-line and elderly soon.. but for general public maybe 2nd 1/4 2021.. maybe, says Fall cases are picking up ..not looking good and the main key will be therapeutics and they are on the way,, he mentioned 2 big names but several on the way.. the 2 mentioned were more about antibody .. which people don't really trust.. so.. at this pace the inhaler should come out with or before a solid vaccine.. but I guess covid-19 is mutating so I don't know it they'll be able to nail it down..
$RLFTF Interesting post by stonkdoctor -ya ho brd
My opinion as an ICU pharmacist.
Past experiences are the minute a COVID patient got through the door at our hospital they got remdesivir. Some still got worse and ended up in our ICU and some of those people died as is the progression of the disease.
No one is all that impressed with remdesivir but it’s all we really have. Basically follow the guidelines and people are still dying day after day. If this gets through a EUA and doctors around the country start giving it to their patients and see good results, word will spread FAST.
Getting it into hospitals is the first step and Dr J was extremely smart in his wording of the application because it’ll be hard for the FDA to say no.
The EUA will state it’s for the sickest of the sick but reality will be if a patient shows any decline while receiving current therapy guidelines, it’ll get ordered ASAP. It’s not going to be only a “few patients” getting dosed once it hits hospitals. All healthcare workers are tired of seeing patient after patient slowly die in front of their eyes while their families are informed over a phone call.
RLF 100 might not be first line treatment initially, but we will see it in action at a very large scale if this EUA gets through. Doctors won’t wait for the patient to be on their death bed to give it. Itll be used frequently, rapidly, and hopefully with great results. Dr J knows what he’s doing.
looks like 12:00 for Dr Yo interview..
$RLFTF Discussion with Dr. Javitt, CEO of NeuroRx | Update on RLF-100 (AVIPTADIL) 10 AM EST
$RLFTF #1 Most read boards Relief Therapeutics 4,401 reads last Hour
SWX: RLF
0.57 CHF +0.016 (2.87%)
Sep 30, 10:45 AM
..still here.. just brewing..
We TROUP HIGH CHEERLEADERS have already kicked the dust...
SWX: RLF
0.55 CHF -0.0080 (1.43%)
Sep 29, 11:35
...moving back up...
COVID-19 Daily Cases On The Rise In Nearly Half Of U.S. States
September 26, 20206:59 PM ET
https://www.npr.org/sections/coronavirus-live-updates/2020/09/26/917275615/covid-19-cases-on-the-rise-in-nearly-half-the-u-s
COVID-19 Daily Cases On The Rise In Nearly Half Of U.S. States
September 26, 20206:59 PM ET
https://www.npr.org/sections/coronavirus-live-updates/2020/09/26/917275615/covid-19-cases-on-the-rise-in-nearly-half-the-u-s
SWX: RLF
0.52 CHF +0.0020 (0.38%)
Sep 25, 4:19
$RVVTF Bringing Psychedelics to Life With Revive Therapeurtics
US Coronavirus: More than 20 states report an uptick in new Covid-19 cases after US tops 200,000 deaths http://a.msn.com/01/en-us/BB19kvQv?ocid=st